Genomic biomarkers of sensitivity to molecularly targeted drugs used to treat NSCLC include mutations or rearrangements in EGFR (3), ALK (4), MET (5), ROS (6) and RET (7), and KRAS (8). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.